The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
High-density lipoprotein cholesterol, coronary artery disease, and cardiovascular mortality
Open accessAbstract
AIMS: High-density lipoprotein (HDL) cholesterol is a strong predictor of cardiovascular mortality. This work aimed to investigate whether the presence of coronary artery disease (CAD) impacts on its predictive value. METHODS AND RESULTS: We studied 3141 participants (2191 males, 950 females) of the LUdwigshafen RIsk and Cardiovascular health (LURIC) study. They had a mean ± standard deviation age of 62.6 ± 10.6 years, body mass index of 27.5 ± 4.1 kg/m², and HDL cholesterol of 38.9 ± 10.8 mg/dL. The cohort consisted of 699 people without CAD, 1515 patients with stable CAD, and 927 patients with unstable CAD. The participants were prospectively followed for cardiovascular mortality over a median (inter-quartile range) period of 9.9 (8.7-10.7) years. A total of 590 participants died from cardiovascular diseases. High-density lipoprotein cholesterol by tertiles was inversely related to cardiovascular mortality in the entire cohort (P = 0.009). There was significant interaction between HDL cholesterol and CAD in predicting the outcome (P = 0.007). In stratified analyses, HDL cholesterol was strongly associated with cardiovascular mortality in people without CAD [3rd vs. 1st tertile: HR (95% CI) = 0.37 (0.18-0.74), P = 0.005], but not in patients with stable [3rd vs. 1st tertile: HR (95% CI) = 0.81 (0.61-1.09), P = 0.159] and unstable [3rd vs. 1st tertile: HR (95% CI) = 0.91 (0.59-1.41), P = 0.675] CAD. These results were replicated by analyses in 3413 participants of the AtheroGene cohort and 5738 participants of the ESTHER cohort, and by a meta-analysis comprising all three cohorts. CONCLUSION: The inverse relationship of HDL cholesterol with cardiovascular mortality is weakened in patients with CAD. The usefulness of considering HDL cholesterol for cardiovascular risk stratification seems limited in such patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In patients who underwent coronary angiography, we have observed that HDL-C correlates inversely with cardiovascular mortality in the absence of CHD, that the relationship of HDL-C to long-term prognosis was weakened in stable coronary heart disease, whereas in clinically unstable patients the relationship was completely abolished [74].”
From HDL cholesterol: reappraisal of its clinical relevance (2017) · cites this paper as [74]
In the citing paper
“In patients who underwent coronary angiography, we have observed that HDL-C correlates inversely with cardiovascular mortality in the absence of CHD, that the relationship of HDL-C to long-term prognosis was weakened in stable coronary heart disease, whereas in clinically unstable patients the relationship was completely abolished [74].”
From HDL cholesterol: reappraisal of its clinical relevance (2017) · cites this paper as [74]
In the citing paper
“In patients who underwent coronary angiography, we have observed that HDL-C correlates inversely with cardiovascular mortality in the absence of CHD, that the relationship of HDL-C to long-term prognosis was weakened in stable coronary heart disease, whereas in clinically unstable patients the relationship was completely abolished [74].”
From HDL cholesterol: reappraisal of its clinical relevance (2017) · cites this paper as [74]
In the citing paper
“In patients with diabetes mellitus, coronary disease, chronic renal insufficiency, cardiovascular risk factors and disorders, the function of HDL is impaired [9, 61, 70–74].”
From HDL cholesterol: reappraisal of its clinical relevance (2017) · cites this paper as [74]
In the citing paper
“CETP inhibition probably also extends the lifespan of dysfunctional HDL.”
From HDL cholesterol: reappraisal of its clinical relevance (2017) · cites this paper as [74]
In the citing paper
“This may not only eliminate the postulated atheroprotective effect but even be harmful if HDL gained adverse properties [9, 74, 108].”
From HDL cholesterol: reappraisal of its clinical relevance (2017) · cites this paper as [74]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.
Gordon, D. J., Probstfield, J. L., Garrison, R. J., Neaton, J. D., Castelli, W. P., Knoke, J. D., Jacobs, D. R., Bangdiwala, S., & Tyroler, H. A. (1989) · Circulation · doi:10.1161/01.cir.79.1.8 · Cited by 3,162
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Effects of dalcetrapib in patients with a recent acute coronary syndrome
Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206797 · Cited by 2,022
Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis
Khera, A. V., Cuchel, M., de la Llera-Moya, M., Rodrigues, A., Burke, M. F., Jafri, K., French, B. C., Phillips, J. A., Mucksavage, M. L., Wilensky, R. L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1001689 · Cited by 1,943
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events
Barter, P., Gotto, A. M., LaRosa, J. C., Maroni, J., Szarek, M., Grundy, S. M., Kastelein, J. J. P., Bittner, V., & Fruchart, J.-C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa064278 · Cited by 1,610
Chapman, M. J., Ginsberg, H. N., Amarenco, P., Andreotti, F., Borén, J., Catapano, A. L., Descamps, O. S., Fisher, E., Kovanen, P. T., Kuivenhoven, J. A., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr112 · Cited by 1,227
Assmann, G., Schulte, H., von Eckardstein, A., & Huang, Y. (1996) · Atherosclerosis · doi:10.1016/0021-9150(96)05852-2 · Cited by 700
HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms
Navab, M., Reddy, S. T., Lenten, B. J. V., & Fogelman, A. M. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.222 · Cited by 666
Glutathione Peroxidase 1 Activity and Cardiovascular Events in Patients with Coronary Artery Disease
Blankenberg, S., Rupprecht, H. J., Bickel, C., Torzewski, M., Hafner, G., Tiret, L., Smieja, M., Cambien, F., Meyer, J., & Lackner, K. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030535 · Cited by 602
Self-citation
Research works printed but not linked: 1
- 2000, Pharmacogenomics, 2, S1
Cited by
Sorted by citations
Vlachopoulos, C., Xaplanteris, P., Aboyans, V., Brodmann, M., Cífková, R., Cosentino, F., De Carlo, M., Gallino, A., Landmesser, U., Laurent, S., et al. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.05.007 · Cited by 716
Self-citationVlachopoulos, C. V., Xaplanteris, P., Aboyans, V., Brodmann, M., Cífková, R., Cosentino, F., Carlo, M. D., Gallino, A., Landmesser, U., Laurent, S., et al. (2015) · HAL · Cited by 590
Self-citationKo, D. T., Alter, D. A., Guo, H., Koh, M., Lau, G., Austin, P. C., Booth, G. L., Hogg, W. E., Jackevicius, C. A., Lee, D. S., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.08.038 · Cited by 340
HDL cholesterol: reappraisal of its clinical relevance
März, W., Kleber, M. E., Scharnagl, H., Speer, T., Zewinger, S., Ritsch, A., Parhofer, K. G., von Eckardstein, A., Landmesser, U., & Laufs, U. (2017) · Clinical Research in Cardiology · doi:10.1007/s00392-017-1106-1 · Cited by 275
Self-citationTardif, J.-C., Ballantyne, C. M., Barter, P., Dasseux, J.-L., Fayad, Z. A., Guertin, M.-C., Kastelein, J. J. P., Keyserling, C., Klepp, H., Koenig, W., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu171 · Cited by 251
Jung, E., Kong, S. Y., Ro, Y. S., Ryu, H. H., & Shin, S. D. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19148272 · Cited by 262
High-density lipoprotein as a modulator of platelet and coagulation responses
van der Stoep, M., Korporaal, S. J. A., & Eck, M. V. (2014) · Cardiovascular Research · doi:10.1093/cvr/cvu137 · Cited by 193
Martin, S. S., Khokhar, A. A., May, H. T., Kulkarni, K. R., Blaha, M. J., Joshi, P. H., Toth, P. P., Muhlestein, J. B., Anderson, J. L., Knight, S., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu264 · Cited by 178
Serum amyloid A: high-density lipoproteins interaction and cardiovascular risk
Zewinger, S., Drechsler, C., Kleber, M. E., Dressel, A., Riffel, J., Triem, S., Lehmann, M., Kopecky, C., Säemann, M. D., Lepper, P. M., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv352 · Cited by 151
Self-citationZhong, G., Huang, S.-Q., Peng, Y., Wan, L., Wu, Y., Hu, T., Hu, J., & Hao, F. (2020) · European Journal of Preventive Cardiology · doi:10.1177/2047487320914756 · Cited by 141
Trimarco, V., Izzo, R., Morisco, C., Mone, P., Manzi, M. V., Falco, A., Pacella, D., Gallo, P., Lembo, M., Santulli, G., et al. (2022) · Hypertension · doi:10.1161/hypertensionaha.122.19912 · Cited by 130
Update on the molecular biology of dyslipidemias
Ramasamy, I. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.10.033 · Cited by 131
Biological Consequences of Dysfunctional HDL
Pirillo, A., Catapano, A. L., & Norata, G. D. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180530110543 · Cited by 122
Sultani, R., Tong, D. C., Peverelle, M., Lee, Y. S., Baradi, A., & Wilson, A. (2019) · Heart Lung and Circulation · doi:10.1016/j.hlc.2019.03.019 · Cited by 119
Zhang, Q., Yin, R., Gao, H., Huang, F., Wu, J., Pan, S., Lin, W., & Yang, D.-Z. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-016-0392-3 · Cited by 117
Kratzer, A., Giral, H., & Landmesser, U. (2014) · Cardiovascular Research · doi:10.1093/cvr/cvu139 · Cited by 112
Self-citationCrichton, G. E., & Alkerwi, A. (2015) · Lipids in Health and Disease · doi:10.1186/s12944-015-0085-3 · Cited by 111
Birner‐Gruenberger, R., Schittmayer, M., Holzer, M., & Marsche, G. (2014) · Progress in Lipid Research · doi:10.1016/j.plipres.2014.07.003 · Cited by 99
HDL and Reverse Remnant-Cholesterol Transport (RRT): Relevance to Cardiovascular Disease
Kontush, A. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.07.005 · Cited by 93
Is a High HDL-Cholesterol Level Always Beneficial?
Franczyk, B., Rysz, J., Ławiński, J., Rysz-Górzyńska, M., & Gluba-Brzózka, A. (2021) · Biomedicines · doi:10.3390/biomedicines9091083 · Cited by 94
Liu, C., Zhang, Y., Ding, D., Li, X., Yang, Y., Li, Q., Zheng, Y., Wang, D., & Ling, W. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.10.111 · Cited by 85
Higher HDL Cholesterol Is Associated with Better Cognitive Function: the Maine-Syracuse Study
Crichton, G. E., Elias, M. F., Davey, A., Sullivan, K., & Robbins, M. A. (2014) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617714000885 · Cited by 82
Zhang, Y., Chen, S., Tian, X., Wang, P., Xu, Q., Xia, X., Zhang, X., Li, J., Liu, F., Wu, S., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01936-y · Cited by 70
Tang, Y., Wang, S., Yi, Q., Xia, Y., & Geng, B. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01497-7 · Cited by 71
HDL particle subpopulations: Focus on biological function
Rached, F. H., Chapman, M. J., & Kontush, A. (2015) · BioFactors · doi:10.1002/biof.1202 · Cited by 73
Cheng, Q., Yang, Y., Shi, X., Yeung, K.-F., Yang, C., Peng, H., & Liu, J. (2020) · NAR Genomics and Bioinformatics · doi:10.1093/nargab/lqaa028 · Cited by 63
Evaluation of Molecularly Imprinted Polymers for Point-of-Care Testing for Cardiovascular Disease
Regan, B., Boyle, F., O’Kennedy, R. J., & Collins, D. (2019) · Sensors · doi:10.3390/s19163485 · Cited by 61
Parra, E. S., Panzoldo, N. B., Zago, V. H. D. S., Scherrer, D. Z., Alexandre, F. A., Bakkarat, J., Nunes, V. S., Nakandakare, E. R., Quintão, E. C. R., Nadruz, W., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114212 · Cited by 60
High-density lipoproteins (HDL): Novel function and therapeutic applications
Darabi, M., & Kontush, A. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2021.159058 · Cited by 52
High-Density Lipoprotein Functionality in Coronary Artery Disease
Kosmas, C. E., Christodoulidis, G., Cheng, J.-W., Lerakis, S., & Vittorio, T. J. (2014) · The American Journal of the Medical Sciences · doi:10.1097/maj.0000000000000231 · Cited by 49
Silbernagel, G., Scharnagl, H., Kleber, M. E., Delgado, G., Stojaković, T., Laaksonen, R., Erdmann, J., Rankinen, T., Bouchard, C., Landmesser, U., et al. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.12.024 · Cited by 43
Self-citationLi, X., Guan, B., Wang, Y., Tse, G., Zou, F., Waleed, K. B., Xia, Y., Wu, S., & Sun, J. (2019) · Scientific Reports · doi:10.1038/s41598-019-50924-4 · Cited by 43
The Therapeutic Potential of Anti-Inflammatory Exerkines in the Treatment of Atherosclerosis
Yu, M., Tsai, S., & Kuo, Y. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061260 · Cited by 39
Association of Serum Retinoic Acid With Risk of Mortality in Patients With Coronary Artery Disease
Liu, Y., Chen, H., Mu, D., Li, D., Yuan, Ž., Jiang, N., Zhang, Y., & Xia, M. (2016) · Circulation Research · doi:10.1161/circresaha.116.308781 · Cited by 40
High-Density Lipoprotein Subclasses, Coronary Artery Disease, and Cardiovascular Mortality
Silbernagel, G., Pagel, P., Pfahlert, V., Genser, B., Scharnagl, H., Kleber, M. E., Delgado, G., Ohrui, H., Ritsch, A., Grammer, T. B., et al. (2017) · Clinical Chemistry · doi:10.1373/clinchem.2017.275636 · Cited by 38
Self-citationvon Eckardstein, A., & Rohrer, L. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000294 · Cited by 33
Silbernagel, G., Chen, Y., Li, H., Lemen, D., Wen, Y., Zhen, Y., Rief, M., Kleber, M. E., Delgado, G., Sarzynski, M. A., et al. (2024) · Circulation · doi:10.1161/circulationaha.124.069272 · Cited by 30
Self-citationHDL and Atherothrombotic Vascular Disease
Annema, W., von Eckardstein, A., & Kovanen, P. T. (2014) · Handbook of experimental pharmacology · doi:10.1007/978-3-319-09665-0_11 · Cited by 34
Guo, J., Chen, M., Yu, H. H., Huang, Y., Zhang, H., Yuan, Z., Zhou, B., & Fu, M. (2023) · Journal of Inflammation Research · doi:10.2147/jir.s425663 · Cited by 32
de Carvalho, L. S. F., Panzoldo, N. B., dos Santos, S. N., Modolo, R., Almeida, B. O., Silva, J. C. Q. E., Nadruz, W., de Faria, E. C., & Sposito, A. C. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.10.103 · Cited by 31
Impaired antioxidant HDL function is associated with premature myocardial infarction
Distelmaier, K., Wiesbauer, F., Blessberger, H., Oravec, S., Schrutka, L., Binder, C., Dostal, E., Schillinger, M., Wojta, J., Lang, I. M., et al. (2015) · European Journal of Clinical Investigation · doi:10.1111/eci.12466 · Cited by 29
Self-citationGenoux, A., Lichtenstein, L., Ferrières, J., Duparc, T., Bongard, V., Vervueren, P., Combes, G., Taraszkiewicz, D., Elbaz, M., Galinier, M., et al. (2016) · BMC Medicine · doi:10.1186/s12916-016-0672-9 · Cited by 28
Schrutka, L., Distelmaier, K., Hohensinner, P. J., Sulzgruber, P., Lang, I. M., Maurer, G., Wojta, J., Hülsmann, M., Niessner, A., & Koller, L. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.116.004169 · Cited by 28
Self-citationMartini, D., Rossi, S., Biasini, B., Zavaroni, I., Bedogni, G., Musci, M., Pruneti, C. A., Passeri, G., Ventura, M., Nuzzo, S. D., et al. (2017) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2017.01.008 · Cited by 27
Huang, Y., Liu, X., Lo, K. K.-H., Liu, L., Yu, Y., Chen, C., Huang, J., Feng, Y., & Zhang, B. (2020) · Clinical Interventions in Aging · doi:10.2147/cia.s271528 · Cited by 27
Li, X., Guo, Y., Zhu, C., Xu, R., Qing, P., Wu, N., Jiang, L., Xu, B., Gao, R., & Li, J. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.114.001412 · Cited by 23
Martínez-Aguilar, E., Orbe, J., Fernández‐Montero, A., Fernandez-Alonso, S., Rodríguez, J. A., Fernandez‐Alonso, L., Páramo, J. A., & Roncal, C. (2017) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2017.04.056 · Cited by 23
Modified and Dysfunctional Lipoproteins in Atherosclerosis: Effectors or Biomarkers?
Orekhov, A. N., & Sobenin, I. A. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180320121137 · Cited by 22
Silbernagel, G., Chen, Y., Rief, M., Kleber, M. E., Hoffmann, M. M., Stojaković, T., Stang, A., Sarzynski, M. A., Bouchard, C., März, W., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad261 · Cited by 21
Self-citationAntipsoriatic treatment extends beyond the skin: recovering of high‐density lipoprotein function
Marsche, G., Holzer, M., & Wolf, P. (2014) · Experimental Dermatology · doi:10.1111/exd.12483 · Cited by 22
Zheng, P., Yin, R., Deng, G., Guan, Y., Wei, B., & Liu, C. (2019) · BMC Cardiovascular Disorders · doi:10.1186/s12872-019-1179-z · Cited by 21
Nakazawa, M., Arashi, H., Yamaguchi, J., Ogawa, H., & Hagiwara, N. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.05.005 · Cited by 18
Risk factors for retinopathy in hemodialysis patients with type 2 diabetes mellitus
Müller, M., Schönfeld, C., Grammer, T. B., Krane, V., Drechsler, C., Genser, B., Kohnen, T., Wanner, C., & März, W. (2020) · Scientific Reports · doi:10.1038/s41598-020-70998-9 · Cited by 18
Self-citationHourcade‐Potelleret, F., Laporte, S., Lehnert, V., Delmar, P., Benghozi, R., Torriani, U., Koch, R., & Mismetti, P. (2015) · Heart · doi:10.1136/heartjnl-2014-306691 · Cited by 17
Guo, Q., Zheng, Y., Tang, J., Wu, T., Yang, X.-M., Zhang, Z.-L., Zhang, J., Yang, Y., Hou, X., Cheng, M.-D., et al. (2020) · Bioscience Reports · doi:10.1042/bsr20202797 · Cited by 17
Zheng, P., Yin, R., Cao, X., Chen, W., Wu, J., & Huang, F. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.713068 · Cited by 17
Mokgalaboni, K., Nkambule, B. B., Ntamo, Y., Ziqubu, K., Nyambuya, T. M., Mazibuko-Mbeje, S. E., Gabuza, K., Chellan, N., Cirilli, I., Tiano, L., et al. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.120068 · Cited by 17
Ding, M., Wennberg, A. M. V., Ek, S., Santoni, G., Gigante, B., Walldius, G., Hammar, N., & Modig, K. (2021) · Scientific Reports · doi:10.1038/s41598-021-03959-5 · Cited by 16
Chen, C., Liu, X., Liu, L., Lo, K. K.-H., Yu, Y., Huang, J., Huang, Y., & Chen, J. (2020) · Risk Management and Healthcare Policy · doi:10.2147/rmhp.s272624 · Cited by 15
Impact of Age and Sex on Subclinical Coronary Atherosclerosis in a Healthy Asian Population
Wong, M. Y. Z., Yap, J. J. L., Huang, W., Tan, S. Y., & Yeo, K. K. (2021) · JACC Asia · doi:10.1016/j.jacasi.2021.05.002 · Cited by 17
Association of the ARL15 rs6450176 SNP and serum lipid levels in the Jing and Han populations.
Sun, J., Yin, R., Shi, G.-Y., Shen, S.-W., Chen, X., Yuan, B., Huang, F., Wang, W., Lin, W., & Pan, S. (2015) · PubMed Central · Cited by 15
Deng, S., Wang, Z., Zhang, Y., Xin, Y., Zeng, C. C., & Hu, X. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01618-2 · Cited by 14
Silbernagel, G., Scharnagl, H., Saely, C. H., Reinthaler, M., Rief, M., Kleber, M. E., LARCHER, B., Chapman, J., Schaefer, J. R., Drexel, H., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10061302 · Cited by 15
Self-citationMahrooz, A., Khosravi-Asrami, O. F., Alizadeh, A., Mohmmadi, N., Bagheri, A., Kashi, Z., Bahar, A., Nosrati, M., & Mackness, M. (2023) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.05.020 · Cited by 14
Liu, H., Guo, Y., Wu, N., Zhu, C., Gao, Y., Qing, P., Li, S., Zhao, X., Zhang, Y., Sun, D., et al. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.06.013 · Cited by 14
Júnior, J. C. D. L., Virginio, V. W., Moura, F. A., Bertolami, A., Bertolami, M. C., Coelho‐Filho, O. R., Zanotti, I., Nadruz, W., de Faria, E. C., de Carvalho, L. S. F., et al. (2019) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2019.09.017 · Cited by 14
Some molecular targets for antihyperlipidemic drug research
Arya, N., Kharjul, M. D., Shishoo, C. J., Thakare, V. N., & Jain, K. S. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.08.013 · Cited by 14
Serum inhibitory factor 1, high-density lipoprotein and cardiovascular diseases
Martinez, L. O., Genoux, A., Ferrières, J., Duparc, T., & Perret, B. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000434 · Cited by 13
Vargas‐Alarcón, G., Pérez-Méndez, O. A., Herrera‐Maya, G., García-Sánchez, C., Martínez‐Ríos, M. A., Peña‐Duque, M. A., Posadas‐Sánchez, R., Posadas‐Romero, C., Escobedo, G., & Fragoso, J. M. (2018) · Lipids · doi:10.1002/lipd.12017 · Cited by 13
Gianfagna, F., Veronesi, G., Guasti, L., Chambless, L. E., Brambilla, P., Corrao, G., Mancia, G., Cesana, G., & Ferrario, M. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.06.029 · Cited by 12
Lukšienė, D., Tamošiūnas, A., Bacevičienė, M., Radišauskas, R., Malinauskiene, V. A., Peasey, A., & Bobák, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100158 · Cited by 14
CANHEART: Is HDL cholesterol a cardiovascular specific risk factor?
Hassan, M. S., & Philip, P. (2017) · Global Cardiology Science and Practice · doi:10.21542/gcsp.2016.34 · Cited by 12
Silbernagel, G., Scharnagl, H., Kleber, M. E., Stojaković, T., & März, W. (2017) · European Journal of Preventive Cardiology · doi:10.1177/2047487317693938 · Cited by 12
Self-citationDistelmaier, K., Schrutka, L., Wurm, R., Seidl, V., Arfsten, H., Cho, A., Manjunatha, S., Perkmann, T., Strunk, G., Lang, I. M., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.06.037 · Cited by 12
Klinische Bedeutung des HDL-Cholesterins
März, W., Kleber, M. E., Scharnagl, H., Speer, T., Zewinger, S., Ritsch, A., Parhofer, K. G., von Eckardstein, A., Landmesser, U., & Laufs, U. (2016) · Herz · doi:10.1007/s00059-016-4499-0 · Cited by 11
Self-citationWang, X., Liu, X., Xie, Z., Tian, J., Huang, X., Zhang, R., Chen, S., Hou, J., & Yu, B. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.12.002 · Cited by 10
Maadani, M., Sarraf, N. S., Alilou, S., Aeinfar, K., Sadeghipour, P., Zahedmehr, A., Fathollahi, M. S., Ghadi, S. I. H., Zavarehee, A., Zolfaghari, M., et al. (2022) · Texas Heart Institute Journal · doi:10.14503/thij-20-7384 · Cited by 9
Liu, R., & Cheng, W. (2024) · Journal of Clinical Hypertension · doi:10.1111/jch.14754 · Cited by 7
Li, S., Liu, Y., Sun, G., Zhou, J., Luo, D., Mao, G., & Xu, W. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1580904 · Cited by 8
Franczyk, B., Młynarska, E., Rysz-Górzyńska, M., Gluba-Brzózka, A., Rysz, J., Sheth, S., Surma, S., Banach, M., & Toth, P. P. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101068 · Cited by 10
The HDL paradox: what does it mean and how to manage low serum HDL cholesterol level?
Cybulska, B., & Kłosiewicz−Latoszek, L. (2014) · Kardiologia Polska · doi:10.5603/kp.a2014.0110 · Cited by 7
Abudouwayiti, A., Sureya, Y., Tuersun, R., Aimaier, S., Didaer, Y., Zhang, X. Y., Zheng, Y.-Y., & Mahemuti, A. (2024) · Journal of Inflammation Research · doi:10.2147/jir.s481085 · Cited by 6
Inhibiting IP6K1 confers atheroprotection by elevating circulating apolipoprotein A-I
Liu, X., Zhang, Z., Aguirre, T., Shipton, M. L., Fu, L., Du, J., Furkert, D., Qi, J., Chin, A. C., Riley, A. M., et al. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156098 · Cited by 7
Epidemiology: Disease Associations and Modulators of HDL-Related Biomarkers
Savolainen, M. J. (2014) · Handbook of experimental pharmacology · doi:10.1007/978-3-319-09665-0_7 · Cited by 6
Li, K.-G., Yin, R., Huang, F., Chen, W., Wu, J., & Cao, X. (2020) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029620902844 · Cited by 6
Li, L., Ma, J., Sun, N., Hu, P., Lin, Y., & Zhang, Q. (2025) · Nutrition & Metabolism · doi:10.1186/s12986-025-00955-8 · Cited by 5
Zheng, P., Chen, L.-Z., Pan, H.-W., Liu, P., & Zheng, Z. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.882728 · Cited by 5
Hong, L.-F., Yang, B., Luo, S.-H., & Li, J. (2014) · Europe PMC (PubMed Central) · doi:10.11909/j.issn.1671-5411.2014.03.015 · Cited by 5
Park, J.-Y. K., & Koehler, K. M. (2019) · Toxicological Sciences · doi:10.1093/toxsci/kfz170 · Cited by 5
Pleiotropic functions and clinical importance of circulating HDL-PON1 complex
Mahrooz, A. (2024) · Advances in clinical chemistry · doi:10.1016/bs.acc.2024.04.003 · Cited by 4
Zheng, P., Yin, R., Guan, Y., Wei, B., Liu, C., & Deng, G. (2020) · Nutrition & Metabolism · doi:10.1186/s12986-020-00533-0 · Cited by 4
Omote, K., Yokota, I., Nagai, T., Sakuma, I., Nakagawa, Y., Kamiya, K., Iwata, H., Miyauchi, K., Ozaki, Y., Hibi, K., et al. (2021) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.59881 · Cited by 4
Nguyen, D. L., Nguyen, C.-T., Ngo-Phan, M.-V., Tran, T. L., Phan, M., Unno, T., & Tran‐Van, H. (2023) · Bioactive Carbohydrates and Dietary Fibre · doi:10.1016/j.bcdf.2023.100384 · Cited by 4
Qiu, Y.-J., Luo, J.-Y., Luo, F., Tian, X.-X., Zeng, L., Zhang, Z., Li, X., & Yang, Y. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.824955 · Cited by 5
Ullah, S., Asad, M., Ullah, F., Shah, M., Fawy, K. F., Zhang, X., Sun, W., Nishan, U., & Badshah, A. (2025) · RSC Advances · doi:10.1039/d5ra07350b · Cited by 3
Physical Inactivity and Clinical Cardiovascular Impact -Updating Narrative Review
(2019) · Worldwide Medicine · doi:10.5455/ww.302644346 · Cited by 2
Ahmed, M., Hashmi, T. M., Shafiq, A., Ashraf, H., Jain, H., Khanji, M. Y., Providencia, R. A., Chahal, C. A. A., Rana, J. S., Farhan, M., et al. (2025) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2025.100610 · Cited by 2
Xu, Y., Yang, Z., Ye, M., Li, M., Tang, X., & Zhou, L. (2020) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.23594 · Cited by 2
Işık, A. C., Erkek, E. T., & Tuna, M. K. (2023) · Istanbul Medical Journal · doi:10.4274/imj.galenos.2023.23682 · Cited by 2
Xiong, Y., Xia, Z., Lu, Y., & Huang, J. (2023) · BMC Gastroenterology · doi:10.1186/s12876-023-02727-1 · Cited by 2
Metadata
- Authors
- Silbernagel, G., Schottker, B., Appelbaum, S., Scharnagl, H., Kleber, M. E., Grammer, T. B., Ritsch, A., Mons, U., Holleczek, B., Goliasch, G., Niessner, A., Boehm, B. O., Schnabel, R. B., Brenner, H., Blankenberg, S., Landmesser, U., & Marz, W.
- Affiliations
- University of Bern (CH)
- Universität Hamburg (DE)
- Medical University of Graz (AT)
- Heidelberg University (DE)
- Innsbruck Medical University (AT)
- German Cancer Research Center (DE)
- Medical University of Vienna (AT)
- Nanyang Technological University (SG)
- University of Zurich (CH)
- Corresponding author
- Silbernagel, G.
- ORCID
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-09-07
- Volume
- 34
- Issue
- 46
- Pages
- 3563-3571
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W2072406176
- Cited by
- 123
- References
- 28
- Citations by year
- 2026: 1 · 2025: 7 · 2024: 6 · 2023: 7 · 2022: 9 · 2021: 12 · 2020: 12 · 2019: 8 · 2018: 8 · 2017: 13 · 2016: 8 · 2015: 13 · 2014: 19
- FWCI
- 13.46
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- European Heart Journal (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- reroDoc Digital Library (submittedVersion)
- Bern Open Repository and Information System (University of Bern) (submittedVersion, other-oa)
- HighWire Press Open Archive (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- European Commission (201668, 305739, LSHM-CT-2004-503485)
- Bundesministerium für Bildung und Forschung
- Fondation de France (2002004994)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- HDL cholesterol, coronary artery disease, cardiovascular mortality, cardiovascular risk stratification, stable coronary artery disease, unstable coronary artery disease, LURIC study, ESTHER cohort
- MeSH terms
- Cardiovascular Diseases, Cause of Death, Coronary Artery Disease, Female, Germany, Humans, Cholesterol, HDL, Male, Middle Aged, Prognosis, Risk Factors, Cohort Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
